153 related articles for article (PubMed ID: 23121504)
21. Evaluation of progression prior to surgery after neoadjuvant chemoradiotherapy with computed tomography in esophageal cancer patients.
Hulshoff JB; Smit JK; van der Jagt EJ; Plukker JT
Am J Surg; 2014 Jul; 208(1):73-9. PubMed ID: 24476969
[TBL] [Abstract][Full Text] [Related]
22. [Long-term outcome of neoadjuvant radiochemotherapy followed by surgery for esophageal cancer: a single institution retrospective study of 102 patients].
Ruffier-Loubière A; Janoray G; Chapet S; de Calan L; Dumont P; Dorval É; Orain I; Calais G
Cancer Radiother; 2015 Aug; 19(5):322-30. PubMed ID: 26215366
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.
Zanoni A; Verlato G; Giacopuzzi S; Weindelmayer J; Casella F; Pasini F; Zhao E; de Manzoni G
Ann Surg Oncol; 2013 Jun; 20(6):1993-9. PubMed ID: 23274533
[TBL] [Abstract][Full Text] [Related]
24. Results of Neoadjuvant Chemoradiotherapy With Docetaxel and 5-Fluorouracil Followed by Esophagectomy to Treat Locally Advanced Esophageal Cancer.
Hamai Y; Hihara J; Emi M; Murakami Y; Kenjo M; Nagata Y; Okada M
Ann Thorac Surg; 2015 Jun; 99(6):1887-93. PubMed ID: 25912745
[TBL] [Abstract][Full Text] [Related]
25. Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone.
Robb WB; Messager M; Dahan L; Mornex F; Maillard E; D'Journo XB; Triboulet JP; Bedenne L; Seitz JF; Mariette C; ; ; ; ;
Br J Surg; 2016 Jan; 103(1):117-25. PubMed ID: 26511668
[TBL] [Abstract][Full Text] [Related]
26. Association of Intervals Between Neoadjuvant Chemoradiation and Surgical Resection With Pathologic Complete Response and Survival in Patients With Esophageal Cancer.
Haisley KR; Laird AE; Nabavizadeh N; Gatter KM; Holland JM; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
JAMA Surg; 2016 Nov; 151(11):e162743. PubMed ID: 27627765
[TBL] [Abstract][Full Text] [Related]
27. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
[TBL] [Abstract][Full Text] [Related]
28. Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy.
Chao YK; Tseng CK; Wen YW; Liu YH; Wan YL; Chiu CT; Chang WC; Chang HK
Ann Surg Oncol; 2013 Sep; 20(9):3000-8. PubMed ID: 23584515
[TBL] [Abstract][Full Text] [Related]
29. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
Franko J; Voynov G; Goldman CD
Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
[TBL] [Abstract][Full Text] [Related]
30. Influence of treatment modality in outcomes for different stages of resectable esophageal adenocarcinomas.
Allan BJ; Pedroso F; Gennis ER; Livingstone AS; Montero A; Lally B; Ardalan B; Koniaris LG; Solomon NL; Franceschi D
Ann Surg Oncol; 2013 May; 20(5):1660-7. PubMed ID: 23456314
[TBL] [Abstract][Full Text] [Related]
31. [Esophageal cancer: outcome according to therapeutic strategy].
Rousseau D; Capitain O; Denis F; Girault S; Poirier AL; Paumier A; Cellier P; Hamy A; Mahé MA; Mesgouez-Nebout N
Cancer Radiother; 2013 Feb; 17(1):10-20. PubMed ID: 23270680
[TBL] [Abstract][Full Text] [Related]
32. Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Jeong Y; Kim JH; Kim SB; Yoon DH; Park SI; Kim YH; Kim HR; Jung HY; Lee GH; Ryu JS
J Surg Oncol; 2014 Apr; 109(5):472-7. PubMed ID: 24301552
[TBL] [Abstract][Full Text] [Related]
33. Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma.
Li SH; Rau KM; Lu HI; Wang YM; Tien WY; Liang JL; Lin WC
Eur J Cardiothorac Surg; 2012 Dec; 42(6):958-64. PubMed ID: 22466694
[TBL] [Abstract][Full Text] [Related]
34. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.
Rizk NP; Venkatraman E; Bains MS; Park B; Flores R; Tang L; Ilson DH; Minsky BD; Rusch VW;
J Clin Oncol; 2007 Feb; 25(5):507-12. PubMed ID: 17290058
[TBL] [Abstract][Full Text] [Related]
35. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
[TBL] [Abstract][Full Text] [Related]
36. Utility of restaging endoscopic ultrasound after neoadjuvant therapy for esophageal cancer.
Griffin JM; Reed CE; Denlinger CE
Ann Thorac Surg; 2012 Jun; 93(6):1855-9; discussion 1860. PubMed ID: 22516835
[TBL] [Abstract][Full Text] [Related]
37. Identification of microRNA Biomarkers of Response to Neoadjuvant Chemoradiotherapy in Esophageal Adenocarcinoma Using Next Generation Sequencing.
Chiam K; Mayne GC; Watson DI; Woodman RJ; Bright TF; Michael MZ; Karapetis CS; Irvine T; Phillips WA; Hummel R; Wang T; Pimlott LK; Marri S; Astill DS; Ruszkiewicz AR; Thompson SK; Hussey DJ
Ann Surg Oncol; 2018 Sep; 25(9):2731-2738. PubMed ID: 29987600
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma.
Gerber N; Ilson DH; Wu AJ; Janjigian YY; Kelsen DP; Zheng J; Zhang Z; Bains MS; Rizk N; Rusch VW; Goodman KA
Dis Esophagus; 2014 Apr; 27(3):235-41. PubMed ID: 23796070
[TBL] [Abstract][Full Text] [Related]
39. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
[TBL] [Abstract][Full Text] [Related]
40. Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma.
Goense L; van Rossum PSN; Xi M; Maru DM; Carter BW; Meijer GJ; Ho L; van Hillegersberg R; Hofstetter WL; Lin SH
Ann Surg Oncol; 2018 Jun; 25(6):1598-1607. PubMed ID: 29569125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]